The EuroBiotech Journal
TECHNICAL REPORT
EBTNA UTILITY GENE TEST

Genetic testing for enhanced S-cone syndrome

Andi Abeshi[1,2], Carla Marinelli[2], Tommaso Beccari[3], Munis Dundar[4], Fabiana D'Esposito[5,6,7] and Matteo Bertelli[2,7]

Abstract

We studied the scientific literature and disease guidelines in order to summarize the clinical utility of genetic testing for enhanced S-cone syndrome (ESCS). The disease has autosomal recessive inheritance, a prevalence of less than one per million, and is caused by mutations in the *NR2E3* gene. Clinical diagnosis is based on clinical findings, ophthalmological examination, electroretinography, color vision testing and optical coherence tomography. The genetic test is useful for confirming diagnosis, and for differential diagnosis, couple risk assessment and access to clinical trials.

[1]MAGI Balkans, Tirana, Albania
[2]MAGI'S Lab, Rovereto, Italy
[3]Department of Pharmaceutical Sciences, University of Perugia, Perugia, Italy
[4]Department of Medical Genetics, Erciyes University Medical School, Kayseri, Turkey
[5]Head and Neck Department, School of Medicine and Surgery, University of Naples "Federico II", Italy
[6]ICORG (Imperial College Ophthalmology Research Group), Western Eye Hospital, London, United Kingdom
[7]MAGI Euregio, Bolzano, Italy

Corresponding author: M. Bertelli
E-mail: info@assomagi.org

Published online: 27 October 2017
doi:10.24190/ISSN2564-615X/2017/S1.15

Enhanced S-cone syndrome

(Other synonyms: retinoschisis with early hemeralopia; Favre hyaloideoretinal degeneration, Goldmann-Favre syndrome) (rarediseases.info.nih.gov)

General information about the disease

Enhanced S-cone syndrome (ESCS) is a rare progressive vitreoretinal dystrophy with early childhood onset, characterized by reduced bilateral visual acuity (from 20/40 to 20/200), hyperopia, subcapsular cataract, hemeralopia, night blindness and increased sensitivity to blue light. . Hyperopia and subcapsular cataract are common associated findings. Other signs related to a severe form, also called Goldman-Favre syndrome, include progressive pigment changes, macular edema or cysts, and foveal retinoschisis.

The estimated prevalence of ESCS is less than one per million.

Diagnosis of ESCS is based on clinical findings, ophthalmological examination, characteristic electroretinographic pattern (1), and optical coherence tomography evidence of retinal thickening (2). The diagnosis is confirmed by molecular genetic analysis of the responsible gene.

Differential diagnosis should consider X-linked retinoschisis, Wagner disease and retinitis pigmentosa.

ESCS is inherited in an autosomal recessive manner and the only known causative gene is *NR2E3* (previously named *PNR*) (OMIM gene: 604485; OMIM disease: 268100).

Pathogenic variants may include sequence variations (small intragenic deletions/insertions, splice-site, missense and nonsense variants). Typically, exon or whole-gene duplications/deletions are not detected.

Aims of test

- To determine the gene defect responsible for the pathology
- To confirm clinical diagnosis of the disease
- To determine carrier status for the disease.

Test characteristics

Experts centers/Published guidelines

The test is listed in the Orphanet database and is offered by 6 accredited medical genetic laboratories in the EU, and in the GTR database, offered by 7 accredited medical genetic laboratories in the US.

The guidelines for clinical use of the test are described in "Genetics home reference" (ghr.nlm.nih.gov) and "American Academy of Ophthalmology" (aao.org).

Test strategy

Sanger sequencing is used for the detection of nucleotide variations in coding exons and flanking introns in the *NR2E3* gene. Sanger sequencing is also used for family segregation studies. To perform molecular diagnosis, a single sample of biological material is normally sufficient. This may be 1 ml blood in a sterile tube with 0.5 ml K3EDTA or 1 ml saliva in a sterile tube with 0.5 ml ethanol 95%. Sampling rarely has to be repeated. Gene-disease associations and the interpretation of genetic variants are rapidly developing fields. It is therefore possible that the genes mentioned in this note may change as new scientific data is acquired. It is also possible that genetic variants today defined as of "unknown or uncertain significance" may acquire clinical importance.

Genetic test results

Positive

Identification of pathogenic variants in *NR2E3* confirms the clinical diagnosis and is an indication for family studies. A pathogenic variant is known to be causative for a given genetic disorder based on previous reports or predicted to be causative based on the loss of protein function or expected significant damage to protein or protein/protein interactions. In this way it is possible to obtain a molecular diagnosis in new/other subjects, establish the risk of recurrence in family members and plan preventive and/or therapeutic measures.

Inconclusive

Detection of a variant of unknown or uncertain significance: a new variation and/or without any evident pathogenic significance or with insufficient or significant conflicting evidence to indicate it is likely benign or likely pathogenic for a given genetic disorder. In these cases, it is advisable to extend testing to the patient's relatives in order to assess variant segregation and clarify its contribution. In some cases it could be necessary to perform further examinations/tests or to do a clinical reassessment of pathological signs.

Negative

The absence of variations in the genomic regions investigated does not exclude a clinical diagnosis but suggests the possibility of:

- alterations that cannot be identified by sequencing, such as large rearrangements that cause loss (deletion) or gain (duplication) of extended gene fragments;
- sequence variations in gene regions not investigated by this test, such as regulatory regions (5' and 3' UTR) and deep intronic regions;
- variations in other genes not investigated by the present test.

Unexpected

Unexpected results may come out from the test, for example information regarding consanguinity; absence of family correlation or the possibility of developing genetically based diseases.

Risk for progeny

Autosomal recessive transmission needs that both healthy carrier parents transmit their disease variant to his/her children. In this case, the probability of having an affected boy or girl is therefore 25%.

Limits of the test

The test is limited by current scientific knowledge regarding the genes and disease.

Analytical sensitivity (proportion of positive tests when the genotype is truly present) and analytical specificity (proportion of negative tests when the genotype is not present)

SANGER: Analytical sensitivity: >99.99%; Analytical specificity: 99.99%.

Clinical sensitivity (proportion of positive tests if the disease is present) and clinical specificity (proportion of negative tests if the disease is not present)

Clinical sensitivity: variations in the *NR2E3* gene are reported in about 75-96% of patients with a clinical diagnosis of ESCS or Goldmann-Favre syndrome (3-5).

Clinical specificity: is estimated at approximately 99.99% [Author's laboratory data] (6).

Prescription appropriateness

The genetic test is appropriate when:

a) the patient meets the diagnostic criteria for the disease;

b) the genetic test has diagnostic sensitivity greater than or equal to other published tests.

Clinical utility

Clinical management	Utility
Confirmation of clinical diagnosis	yes
Differential diagnosis	yes
Access to clinical trial (7)	yes
Couple risk assessment	yes

References

1. Sustar M, Perovšek D, Cima I, Stirn-Kranjc B, Hawlina M, Brecelj J. Electroretinography and optical coherence tomography reveal abnormal post-photoreceptoral activity and altered retinal lamination in patients with enhanced S-cone syndrome. Doc Ophthalmol 2015 Jun;130(3):165-77. PubMed PMID: 25663266. Epub 2015/02/07.
2. Jacobson SG, Sumaroka A, Aleman TS, Cideciyan AV, Schwartz SB,

Roman AJ, et al. Nuclear receptor NR2E3 gene mutations distort human retinal laminar architecture and cause an unusual degeneration. Hum Mol Genet. 2004 Sep 1;13(17):1893-902. PubMed PMID: 15229190. Epub 2004/06/30.

3. Audo I, Michaelides M, Robson AG, Hawlina M, Vaclavik V, Sandbach JM, et al. Phenotypic variation in enhanced S-cone syndrome. Invest Ophthalmol Vis Sci. 2008 May;49(5):2082-93. PubMed PMID: 18436841.
4. Bandah D, Merin S, Ashhab M, Banin E, Sharon D. The spectrum of retinal diseases caused by NR2E3 mutations in Israeli and Palestinian patients. Arch Ophthalmol. 2009 Mar;127(3):297-302. PubMed PMID: 19273793.
5. Wright AF, Reddick AC, Schwartz SB, Ferguson JS, Aleman TS, Kellner U, et al. Mutation analysis of NR2E3 and NRL genes in Enhanced S Cone Syndrome. Hum Mutat. 2004 Nov;24(5):439. PubMed PMID: 15459973.
6. Chen B, Gagnon M, Shahangian S, Anderson NL, Howerton DA, Boone JD. Good Laboratory Practices for Molecular Genetic Testing for Heritable Diseases and Conditions. MMWR Recomm Rep. 2009 Jun 12; 58 (RR-6):1-37. PubMed PMID: 19521335.
7. Stone EM, Aldave AJ, Drack AV, Maccumber MW, Sheffield VC, Traboulsi E, et al. Recommendations for genetic testing of inherited eye diseases: report of the American Academy of Ophthalmology task force on genetic testing. Ophthalmology. 2012 Nov;119(11):2408-10. PubMed PMID: 22944025. Epub 2012/09/01.